donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > QURE uniQure NV > Key Indicators
QURE uniQure NV
19.100
+0.430+2.30%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
79.47% 23.8309 61.61% 16.028 61.61% 16.028 570.63% 250.5744
Fixed Assets Turnover(T)
1117.17% 8.1427 1148.8% 8.2202 1148.8% 8.2202 7343.3% 8.1199
Total Asset Rate(T)
863.03% 0.9373 858.72% 0.9116 858.72% 0.9116 5940.27% 0.8895
ROIC
270.6% 65.520% 286.92% 64.345% 286.92% 64.345% 243.17% 65.255%
ROE
258.32% 83.767% 278% 78.503% 278% 78.503% 236.63% 78.344%
ROA
262.52% 57.889% 280.94% 57.341% 280.94% 57.341% 241.36% 57.003%
FCF to Sales
-- 54.422% -- 51.626% -- 51.626% -- 56.214%
FCF to Net Income
-- 88.114% -- 82.078% -- 82.078% -- 87.717%
Efficiency Ratios
ROE 5 Year Average
-- -- 46.04% -36.115% -- -- -- --
ROA 5 Year Average
-- -- 51.96% -16.565% -- -- -- --
Average 5 Years ROIC
-- -- 46.97% -28.287% -- -- -- --
Profitability Ratios TTM
Gross Margin
-- -- -- 95.234% -- 95.234% -- --
Operating Margin
116.02% 57.296% 117.73% 59.278% 117.73% 59.278% 102.42% 60.009%
Net Margin
116.88% 61.763% 118.87% 62.898% 118.87% 62.898% 102.34% 64.085%
EBITDA Margin
117.7% 0.6526% 119.6% 0.6633% 119.6% 0.6633% 102.56% 0.6432%
R & D Expense Ratio
-91.29% 29.680% -91.61% 27.390% -91.61% 27.390% -98.63% 26.560%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-45.67% 23.746% -19.42% 21.812% -19.42% 21.812% -40.68% 17.135%
Total Assets to Common Equity
-12.84% 138.672% -2.68% 135.820% -2.68% 135.820% -14.75% 131.125%
Debt to Asset Ratio
-46.2% 24.800% -22.34% 22.781% -22.34% 22.781% -42.16% 18.116%
Current Ratio
47.08% 12.9354 80.41% 17.0889 80.41% 17.0889 64.39% 14.1652
Quick Ratio
52% 12.6069 81.79% 16.7294 81.79% 16.7294 63.57% 13.8902
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- 517.99% 259.437% -- -- -- --
Revenue CAGR(5Y)
-- -- 183.59% 83.628% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
CEO: Kapusta, Matthew Craig
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...